{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:47:09Z","timestamp":1793119629077,"version":"4.5.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","heartandlung.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart & Lung"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.hrtlng.2025.05.008","type":"journal-article","created":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T09:52:11Z","timestamp":1747475531000},"page":"114-122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Efficacy and safety of Nintedanib in idiopathic pulmonary fibrosis: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"73","author":[{"given":"Shamikha","family":"Cheema","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9490-5365","authenticated-orcid":false,"given":"Muhammad Nabeel","family":"Saddique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurag","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayesha","family":"Sehar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umaima","family":"Cheema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Shahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Faique","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hammad","family":"Javaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria Chiara","family":"Lanari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Nawaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hrtlng.2025.05.008_bib0001","doi-asserted-by":"crossref","first-page":"191","DOI":"10.62347\/DAKS5508","article-title":"Cellular therapies for idiopathic pulmonary fibrosis: current progress and future prospects","volume":"13","author":"Le","year":"2024","journal-title":"Am. J. Stem. Cells"},{"key":"10.1016\/j.hrtlng.2025.05.008_bib0002","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.jpainsymman.2019.12.364","article-title":"Idiopathic pulmonary fibrosis: a review of disease, pharmacological, and nonpharmacological strategies with a focus on symptoms, function, and health-related quality of life","volume":"59","author":"Rozenberg","year":"2020","journal-title":"J. Pain Symptom Manag."},{"key":"10.1016\/j.hrtlng.2025.05.008_bib0003","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02279-2019","article-title":"Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry","volume":"56","author":"Behr","year":"2020","journal-title":"Europ. Respirat. J."},{"key":"10.1016\/j.hrtlng.2025.05.008_bib0004","first-page":"377","article-title":"Advances in the management of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis","author":"Liu","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.hrtlng.2025.05.008_bib0005","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of Nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl. J. Med."},{"key":"10.1016\/j.hrtlng.2025.05.008_bib0006","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1136\/thoraxjnl-2016-209701","article-title":"Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension","volume":"73","author":"Richeldi","year":"2018","journal-title":"Thorax"},{"key":"10.1016\/j.hrtlng.2025.05.008_bib0007","article-title":"Clinical use of nintedanib in patients with idiopathic pulmonary fibrosis","volume":"4","author":"Case","year":"2017","journal-title":"BMJ Open Respir. Res."},{"key":"10.1016\/j.hrtlng.2025.05.008_bib0008","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000448288","article-title":"Insights from the German Compassionate Use Program of Nintedanib for the treatment of idiopathic pulmonary fibrosis","volume":"92","author":"Bonella","year":"2016","journal-title":"Respiration"},{"key":"10.1016\/j.hrtlng.2025.05.008_bib0009","doi-asserted-by":"crossref","DOI":"10.1007\/s41030-024-00271-1","article-title":"Patient profile-based management with Nintedanib in patients with idiopathic pulmonary fibrosis","author":"Viswanathan","year":"2024","journal-title":"Pulm. Ther."},{"key":"10.1016\/j.hrtlng.2025.05.008_bib0010","article-title":"Real-world clinical profile and safety of Nintedanib in systemic sclerosis-associated interstitial Lung Disease: A subgroup analysis of interstitial lung disease data from an interstitial Lung disease (ILD) specialty clinic in India","volume":"16","author":"Behera","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.hrtlng.2025.05.008_bib0011","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3390\/ph17010119","article-title":"Functional progression after dose suspension or discontinuation of nintedanib in idiopathic pulmonary fibrosis: a real-life multicentre study","volume":"17","author":"Ruaro","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.hrtlng.2025.05.008_bib0012","unstructured":"Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions : Cochrane Book Series n.d."},{"key":"10.1016\/j.hrtlng.2025.05.008_bib0013","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S2213-2600(18)30339-4","article-title":"Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON","volume":"7","author":"Crestani","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.hrtlng.2025.05.008_bib0014","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000527308","article-title":"Observational, multicenter study on the efficacy, tolerability, and safety of Nintedanib in patients with idiopathic pulmonary fibrosis older than 80 years","volume":"102","author":"Mondoni","year":"2023","journal-title":"Respiration"},{"key":"10.1016\/j.hrtlng.2025.05.008_bib0015","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1159\/000521138","article-title":"Nintedanib in IPF: post hoc analysis of the Italian FIBRONET observational study","volume":"101","author":"Harari","year":"2022","journal-title":"Respiration"},{"key":"10.1016\/j.hrtlng.2025.05.008_bib0016","doi-asserted-by":"crossref","first-page":"00172","DOI":"10.1183\/23120541.00172-2019","article-title":"Efficacy and safety of nintedanib in a Greek multicentre idiopathic pulmonary fibrosis registry: a retrospective, observational, cohort study","volume":"6","author":"Antoniou","year":"2020","journal-title":"ERJ Open Res."},{"key":"10.1016\/j.hrtlng.2025.05.008_bib0017","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12931-015-0276-5","article-title":"Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis","volume":"16","author":"Corte","year":"2015","journal-title":"Respir. Res."},{"key":"10.1016\/j.hrtlng.2025.05.008_bib0018","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s00228-024-03720-7","article-title":"Real-world safety and effectiveness of pirfenidone and nintedanib in the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis","volume":"80","author":"Kou","year":"2024","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.hrtlng.2025.05.008_bib0019","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.rmed.2016.02.001","article-title":"Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS(\u00ae) trials","volume":"113","author":"Richeldi","year":"2016","journal-title":"Respir. Med."},{"key":"10.1016\/j.hrtlng.2025.05.008_bib0020","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00752-2023","article-title":"Effects of nintedanib on symptoms in patients with progressive pulmonary fibrosis","volume":"63","author":"Wijsenbeek","year":"2024","journal-title":"Eur. Respir. J."}],"container-title":["Heart & Lung"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0147956325001104?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0147956325001104?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T04:14:14Z","timestamp":1750911254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0147956325001104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":20,"alternative-id":["S0147956325001104"],"URL":"https:\/\/doi.org\/10.1016\/j.hrtlng.2025.05.008","relation":{},"ISSN":["0147-9563"],"issn-type":[{"value":"0147-9563","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of Nintedanib in idiopathic pulmonary fibrosis: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Heart & Lung","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hrtlng.2025.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}